香港醫思醫療集團(02138.HK)預期中期銷售額增長逾10%
格隆匯10月15日丨香港醫思醫療集團(02138.HK)公佈,截至2019年9月30日止的6個月,本集團預期錄得:(i)期內銷售額將不少於10億港元;(ii)期內銷售額較去年同期增長將不少於10%;(iii)期內6個月的每一個月的月銷售額較去年同期相比有所增加;及(iv)期內本集團所提供的醫療服務銷售額較去年同期增長將不少於50%。
董事會相信引致該增加是主要由於(i)大眾對本集團提供醫療服務的強勁需求屬於剛性而該需求持續成為本集團的主要增長動力;及(ii)儘管經營環境充滿挑戰,本集團於期內積極地提高與客户的互動並以促銷活動帶動銷售而同時本集團提供的醫療服務對本集團的貢獻有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.